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Background: Diagnosing systemic juvenile idiopathic arthritis (SJIA) can be extremely challenging if typical arthritis
is lacking. A variety of biomarkers have been described for the diagnosis and management of SJIA. However, very
few markers have been well-validated. In addition, increasing numbers of biomarkers are identified by high
throughput or multi-marker panels.
Method: We identified diagnostic or prognostic biomarkers by systematic literature review, evaluating each
according to a predefined level of verification, validation or clinical utility. Diagnostic biomarkers were those
identifying SJIA versus (1) non-SJIA conditions or healthy controls (HC) or (2) other non-systemic JIA subtypes.
Prognostic biomarkers were those specifically tested for the prediction of (1) disease flare, (2) increased disease activity +/-
discrimination of active versus inactive disease, or (3) macrophage activation syndrome (MAS).
Results: Fifty-five studies fulfilled the inclusion criteria identifying 68 unique biomarkers, of which 50/68 (74 %) were
investigated by only a single research group. Candidate marker verification and clinical utility was evaluated according to
whether markers were readily and reliably measurable, investigated by independent study groups, discovered by more
than one method (i.e. verified markers) and validated in independent cohorts. This evaluation revealed diagnostic
biomarkers of high interest for further evaluation in the diagnostic approach to SJIA that included heme oxygenase-1,
interleukin-6 (IL-6), IL-12, IL-18, osteoprotegerin, S100 calcium-binding protein A12 (S100A12) and S100A8/A9.
Conclusion: In summary, a number of biomarkers were identified, though most had limited evidence for their use.
However, our findings combined with the identified studies could inform validation studies, whether in single or
multi-marker assays, which are urgently needed.Background
Systemic juvenile idiopathic arthritis (SJIA), or Still’s dis-
ease/syndrome, is a childhood rheumatic condition that
is typically characterized by spiking fever in a quotidian
pattern, transient rash and arthritis. Patients may alter-
nate between periods of disease activity (flare) and in-
active disease. SJIA accounts for around 10–20 % of
juvenile idiopathic arthritis (JIA), which has an incidence
of around 6.6–15 per 100,000 children [1]. Although de-
fined as a subtype of JIA, patients often present with ra-
ther unspecific signs and symptoms initially, with the
hallmark fever of unknown origin, but without chronic
arthritis. Diagnosing SJIA is challenging in these cases as* Correspondence: dfoell@uni-muenster.de
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drome rather than classical autoimmune arthritis [2, 3].
Accordingly, most clinical symptoms can be attributed
to dysregulated innate immune mechanisms with only
minor involvement of adaptive immunity. Gene expres-
sion studies of circulating cells show increased levels of
transcripts, reflecting monocyte/macrophage-associated
activation in SJIA [4–6]. The innate immune cells such
as monocytes and macrophages are thought to be drivers
of SJIA, producing several mediators implicated in the
pathogenesis of SJIA, including interleukin-1 (IL-1), IL-6
and IL-18 and phagocyte-specific S100 proteins [7]. IL-1
in particular seems to have a prominent role in SJIA.
Serum from patients with SJIA induces the transcription
of genes of the innate immune system including IL-1 in
peripheral blood mononuclear cells (PBMC). Furthermore,le is distributed under the terms of the Creative Commons Attribution 4.0
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cantly more IL-1β in comparison with monocytes from
healthy controls [6].
Significant challenges to improving the clinical care of
patients with SJIA include the discrimination of SJIA
from other causes of fever, evidence-based evaluation of
response to treatment, detection and limitation of sub-
clinical inflammation and discrimination of SJIA without
macrophage activation syndrome (MAS) from SJIA with
MAS [8]. MAS is a serious complication of SJIA with a
10 % mortality risk, defined as an acute episode of over-
whelming inflammation and characterized by activation
and expansion of T lymphocytes and hemophagocytic
macrophages. In the early stages, development of MAS
is difficult to predict and diagnostic and prognostic bio-
markers might enable early intervention.
These challenges could be addressed by the identifica-
tion and validation of clinically relevant biomarkers, of
which those circulating in serum and plasma are useful
and easily obtainable from peripheral blood [9–13].
Mechanistic markers are those that are elevated or de-
creased in response to underlying pathological processes,
whereas proxy markers, such as C-reactive protein
(CRP), do not have a definite role in the pathology of
the disease, and are non-specific markers of inflamma-
tion [14]. Therefore, measurement of a mechanistic bio-
marker can quantify a pathologic process. With such
quantification, a level of severity can be defined, and cut-
offs determined, allowing the use of such biomarkers asFig. 1 Biomarker need in clinical context. Typical clinical sequence in syste
clinical resolution and flare. Specific time points where there is a need for diagn
indicated as follows: D1 SJIA versus other non-JIA conditions, D2 SJIA versus oth
for flare, P2 prognostic for increased disease activity, P3 prognostic for macroph
Adapted from Hinze et al. 2015 [8]treatment targets (Fig. 1) [8, 15]. Diagnostic biomarkers,
proxy or mechanistic, can aid detection of a disease or
confirm it in uncertain cases e.g., evolving SJIA versus
sepsis [15, 16].
Although a number of publications describe potential
biomarkers, none have been recently validated or used
in clinical studies aside from the IL-1 family cytokines
and the S100-proteins, S100A12 and S100A8/A9 [17].
To date, discovery studies vastly outnumber validation
studies, which are more challenging to perform given
their requirement for independent cohorts and statisti-
cally valid sample sizes. Additionally, the number of
identified candidates is usually large and the cost of
validation high, leading to a need for unbiased
prioritization of candidates for validation [18].
In conclusion, a combination of sensitive biomarkers
could allow targeted and personalized treatment and im-
prove treatment outcomes [8]. We therefore identified
current candidate diagnostic and prognostic biomarkers
from the literature, additionally evaluating their potential
for validation/clinical use, function and association with
other identified biomarkers. We also discuss the current
and future potential of biomarkers for SJIA.
Method
Search criteria
A PubMed search was performed using the search terms
as follows: "Arthritis, Juvenile“[Mesh] AND ((”2000/11/
01"[PDAT]: “2015/11/01”[PDAT]) AND “humans”[MeSHmic juvenile idiopathic arthritis (SJIA) from disease onset, diagnosis to
ostic and prognostic biomarkers are indicated. Diagnostic markers are
er JIA subtypes. Prognostic markers are indicated as follows: P1 prognostic
age activation syndrome (MAS) or differentiating MAS from SJIA flare.
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keywords: 1) cytokine (“cytokines”[MeSH Terms] OR
“cytokines”[All Fields] OR “cytokine”[All Fields]) (n = 544
individual studies identified), OR 2) biomarker (“biological
markers”[MeSH Terms] OR (“biological”[All Fields] AND
“markers”[All Fields]) OR “biological markers”[All Fields]
OR “biomarker”[All Fields]) (n = 307), OR 3) valid-
ation (n = 114). Abstracts of identified studies were
reviewed and any fulfilling exclusion criteria at the
outset were excluded, and the full text scrutinized for
those remaining.
Inclusion and exclusion criteria
Inclusion criteria were as follows: studies in which
serum or plasma markers were analysed; original re-
search studies; studies that specifically addressed the
biomarkers with the diagnostic or prognostic functions
as indicated in Table 1 and studies that also included
SJIA-specific analyses. Exclusion criteria were: case stud-
ies or review articles; studies that included fewer than
three patients with SJIA; studies with only negative find-
ings reported (i.e. no statistically significant finding for
the candidate marker for the use evaluated) and studies
describing functional/cell-based assays or enzyme activ-
ity assays. We also excluded studies on adult-onset Still’s
disease (AOSD) [19] and genetic array/genotype or
phenotype studies that described individual patients ra-
ther than disease signatures, without evaluation of indi-
vidual biomarkers, even if performed as unbiased
discovery studies. Genetic markers and gene expression
profiles in SJIA have been previously discussed in a re-
view by Nirmala et al. [20].
Data analysis and categorisation of biomarkers
Details recorded from identified studies included the
aims, numbers of included patients and methods of bio-
marker assessment (Additional file 1). Biomarkers from
each study were categorised as diagnostic (discriminat-
ing SJIA from non-JIA disorders or healthy controls
(HC) termed “D1 biomarkers” or differentiating SJIA
from other JIA subtypes, “D2 biomarkers”) or prognostic
(for flare, “P1 biomarkers”, increased disease activity orTable 1 Diagnostic and prognostic criteria for inclusion
Biomarker function Description
Diagnostic D1: SJIA versus other non-arthritis conditions or H
D2: SJIA versus other JIA subtypes
Prognostic P1: for flare (or relapse)
P2: for increased disease activity and/or the
discrimination of active and inactive disease
P3: for MAS or discriminating MAS from SJIA flarediscriminating active versus inactive disease, “P2 bio-
markers”, or prognostic for MAS or differentiating SJIA
with and without MAS, “P3 biomarkers”), as defined in
Table 1, according to the study objectives, and indicated
in Fig. 1.
Evaluation of identified markers
Identified candidate biomarkers were scored and ranked
by their potential to reach validation or clinical use, with
potentially spurious or unreproducible candidate find-
ings ranked the lowest. The biomarker scoring system
(BMS) used (Table 2) was developed to identify whether
identified candidates (1) were readily measurable, i.e. in
standard collected biological samples and without spe-
cial equipment, (2) had been measured by independent
study groups, as confirmation that the biomarker is de-
tectable, (3) had been discovered by more than one
method, e.g., proteomic and enzyme-linked immuno-
sorbent assay (ELISA) methods, (4) had been measured
by an established assay, i.e. an assay that is well-
described, with normal cutoff values available, as this
would allow easier translation to clinical practice and fi-
nally (5) had been validated for the stated clinical ques-
tion. Each evaluation question making up the BMS
(Table 2) was answered using only the information col-
lected during the review process, and each of the in-
cluded five questions was scored 0 or 1.
Results and discussion
Identified candidate biomarkers
A total of 57 studies describing 68 unique biomarkers
were identified (Table 3). All reported biomarkers
were identified in serum unless otherwise indicated
(Additional file 1: Table S1). The mean number of pa-
tients with SJIA included in studies was 21 (range 4–60).
There were 50 biomarkers (74 %) investigated in studies
performed by a single research group and 29/57 studies
evaluated a single biomarker. Biomarkers included cyto-
kines, soluble receptors, antibodies, alarmins and other
functional molecules (Table 3). The most studied bio-
markers were IL-18 (n = 7 individual studies), IL-6 (n = 5),
S100A8/A9 (n = 5), S100A12 (n = 4) and soluble CD25Biomarkers identified (n) Number of studies in which






Table 2 Scoring system used to perform an unbiased
evaluation of identified biomarkers
Q1 Readily measurable (e.g. in serum) Yes = 1 No = 0
Q2 Measured by more than one independent
study group
Yes = 1 No = 0
Q3 Discovered by more than one single method Yes = 1 No = 0
Q4 Measured by a reproducible assay Yes = 1 No = 0
Q5 Validated in a validation cohort Yes = 1 No = 0
Maximum score = 5, minimum score = 0
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markers, namely S100A8/A9 and S100A12, were de-
scribed in JIA (but not SJIA) validation studies [21].
Hepcidin, also included as a diagnostic marker, was vali-
dated for differentiating SJIA-associated anaemia from an-
aemia of other causes, but not specifically for SJIA
diagnosis [22].
Current clinical uses of identified biomarkers
This study identified some well-established markers of
inflammation and/or SJIA, such as the S100-proteins
(S100A12 and S100A8/A9 complex), IL-18 and IL-6,
autoantibodies, non-specific inflammatory markers and
some markers not classically associated with SJIA, such
as B cell markers. S100A8/A9 is a predictive biomarker
for subclinical disease activity and a predictor of JIA re-
lapse after stopping medication [17, 21, 23]. IL-18 con-
centration is a known marker of disease activity in SJIA,
while IL-18 and IL-6 can define subsets of SJIA [24–26].
While IL-6 and IL-1 are targets of the biological therap-
ies tocilizumab, canakinumab, rilonacept and anakinra,
respectively, neither cytokine is routinely measured in
patients [27–30]. IL-1b, as already discussed, is usually
undetectable in serum and IL-18 is not regularly mea-
sured due to technical limitations in performing bioas-
says [31]; however the reason for IL-6 not being used in
routine care is unclear [32, 33].
A number of autoantibodies were identified as candi-
date biomarkers, including rheumatoid factor (RF), anti-
nuclear antibodies (ANA) and anti-citrullinated protein
antibodies (ACPA). RF has long been recognised as dis-
tinguishing RF-positive and RF-negative forms of polyar-
thritis (JIA subtypes) [34]. ANA are routinely evaluated
in JIA as a screening factor for JIA-associated uveitis
[35]. However, Shin et al. showed that ANA levels can
change over time in patients with SJIA, which is a find-
ing replicated by Huegle et al. [36, 37] ACPA are associ-
ated with joint damage, and are included in the
classification criteria for rheumatoid arthritis, though
they do not have an established use in SJIA [38–40].
CRP and ferritin, which are routinely measured, non-
specific, acute phase reactants used as surrogate
markers, were described as baseline parameters in mostof the identified studies, but were not the subject of in-
vestigation in the studies, so were therefore excluded
from Tables 1 and 3 and from further analyses. Other
non-specific identified biomarkers of inflammation were
serum amyloid (SAA), fibrin D-dimer and complement 4
(C4). While previously important in detecting long-term
complications of inflammation such as amyloidosis, SAA
measurement has become less important since the intro-
duction of biological treatments, which have reduced
complications in SJIA.
Candidate biomarkers categorised as diagnostic or
prognostic
Some biomarkers were identified in more than one study
as described above and evaluated for more than one
clinical question (Tables 1 and 3). There were 51
markers characterised as diagnostic, 33 as prognostic
and 16 were both diagnostic and prognostic (Table 3):
these were ACPA, A proliferation-inducing ligand
(APRIL), B-cell activating factor (BAFF), cartilage oligo-
meric matrix protein (COMP), follistatin-like protein 1
(FSTL-1), heme oxygenase-1 (HO-1), interferon gamma
(IFNg), IL-10, IL-18, IL-18 binding protein (IL-18BP),
IL-6, S100A12, S100A8/A9, SAA, soluble ST2/IL-1
receptor-like 1 (sST2) and transthyretin (TTr).
Evaluation of identified markers by clinical question
There were 36 biomarkers that differentiated SJIA from
HC or other non-JIA disease (D1 biomarkers) and 25
markers differentiated SJIA from other JIA subtypes (D2
biomarkers). Of the prognostic markers, 14 P1 (flare), 15
P2 (disease activity) and seven P3 (MAS) biomarkers
were identified (Table 1). Ten biomarkers were common
to D1 and D2 (Fig. 2a); however, few markers overlapped
between the prognostic groups (Fig. 2b). This analysis
suggests that some biomarkers could have broad use as
diagnostic or prognostics markers, rather than being
useful only for specific questions. These markers might
therefore be more useful than others in a clinical setting,
and might therefore be prioritised for validation.
Evaluation of candidate markers
For unbiased and valid results, biomarker evaluation
should be performed according to a predefined hypoth-
esis [41] in order to identify candidates more likely to be
specific, rather than a high number of unspecific candi-
dates. High throughput methods are increasingly sensi-
tive and producing ever larger numbers of candidate
biomarkers; however, they can still be impeded by meth-
odological limitations, such as in LC-MS/MS, by the
presence of high abundant proteins [42, 43]. Therefore,
careful and evidence-based hypothesis-driven evaluation
and prioritisation of candidates for validation studies is
vital. While discovery studies are usually unbiased, the
Table 3 Identified serum and plasma biomarkers
Biomarker Detection method Intended use
(P/D) + Reference
BMS scorea Q1 + Q2 +
Q3 + Q4 + Q5 = total
Abbreviation/gene name Full/alternative name D P
A2M Alpha-2-macroglobulin Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
AB-oxLDL Antibodies to oxidized low-density lipoprotein Commercial ELISA [68] 1 + 0 + 0 + 1 + 0 = 2
ACAN Aggrecan core protein, cartilage-specific
core protein
Immunoassay [69] 1 + 0 + 0 + 1 + 0 = 2
ACPA Anti-citrullinated protein antibodies Commercial ELISA [39] [39] 1 + 0 + 0 + 1 + 0 = 2
ACT Alpha-1-antichymotrypsin Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
AECA Anti-endothelial cell antibodies In-house ELISA [70] 1 + 0 + 0 + 1 + 0 = 2
AGP1 Alpha-1-acid-glycoprotein Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
ANA Antinuclear antibody Fluorescence assay [36] 1 + 1 + 0 + 1 + 0 = 3
Commercial ELISA [37]
Anti-BiP Anti-immunoglobulin binding protein/glucose
regulated protein 78 (GRP78)
In-house ELISA [71] 1 + 0 + 0 + 1 + 0 = 2
Anti-CCP Anti-cyclic citrullinated peptide Commercial ELISA [72] 1 + 0 + 0 + 1 + 0 = 2
APO A1 Apolioprotein A1 Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
APO VI Apolipoprotein VI Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
APRIL A proliferation-inducing ligand Commercial ELISA [73] [73] 1 + 0 + 0 + 1 + 0 = 2
B2M Beta -2-microglobulin Not indicated [74] 1 + 0 + 0 + 1 + 0 = 2
BAFF B-cell activating factor Commercial ELISA [73] [73] 1 + 0 + 0 + 1 + 0 = 2
C4 Complement C4 Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
CCL3 Chemokine (C-C motif) ligand 3 Luminex assay [57] 1 + 0 + 0 + 1 + 0 = 2
CD10 Cluster of differentiation antigen 10, also
called neprilysin
Fluorimetric assay [75] 1 + 0 + 0 + 1 + 0 = 2
CFH Complement factor H Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
COMP Cartilage oligomeric matrix protein Commercial ELISA [39] [39] 1 + 1 + 0 + 1 + 0 = 3
[76] [77]
[78]
CXCL9 Chemokine (C-X-C Motif) ligand 9 Luminex assay [57] 1 + 0 + 0 + 1 + 0 = 2
Fibrin D-dimer Commercial assay [79] 1 + 0 + 0 + 1 + 0 = 2
FSTL-1 Follistatin-like protein 1 Commercial ELISA [80] [80] 1 + 1 + 0 + 1 + 0 = 3
[81]
GHRL Ghrelin, appetite regulating hormone Commercial ELISA [82] 1 + 0 + 0 + 1 + 0 = 2
GSN Gelsolin Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
Hepcidin Peptide hormone, released by hepatocytes Commercial assay [22] 1 + 0 + 0 + 1 + 0 = 2
HMGB1 High mobility group box protein 1 Commercial assay [83] 1 + 0 + 0 + 1 + 0 = 2
HO-1 Heme oxygenase-1 Commercial ELISA [84] [85] 1 + 1 + 0 + 1 + 1 = 4
HP Haptoglobin Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
IFNg Interferon gamma Commercial ELISA [86] [86] 1 + 0 + 0 + 1 + 0 = 2
IgA RF Ig A rheumatoid factor isotype In-house ELISA [87] 1 + 0 + 0 + 1 + 0 = 2
IgM RF Ig M rheumatoid factor isotype In-house ELISA [87] 1 + 0 + 0 + 1 + 0 = 2
IL-10 Interleukin-10 Commercial ELISA [88] [85] 1 + 0 + 0 + 1 + 0 = 2
IL-12 Interleukin-12 Luminex assay [57] 1 + 1 + 1 + 1 + 0 = 4
Commercial ELISA [89]
IL-18 Interleukin-18 Commercial assay
Luminex assay
[25] 1 + 1 + 1 + 1 + 0 = 4
[57] [24]
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IL-18BP Interleukin-18 binding protein Commercial assay [86] 1 + 1 + 0 + 1 + 0 = 3
[90] [90]
IL-1b Interleukin-1beta Commercial ELISA [89] 1 + 0 + 0 + 1 + 0 = 2
IL-6 Interleukin-6 Luminex assay
Commercial ELISA








[57] 1 + 1 + 0 + 1 + 0 = 3
[86]
[93]
LGALS3 Galectin-3 Commercial ELISA [94] 1 + 0 + 0 + 1 + 0 = 2
MIF Macrophage migration inhibitory factor Luminex assay [57] 1 + 0 + 0 + 1 + 0 = 2
MMP-3 Matrix metalloprotinease-3/stromelysin-1 (SL-1) Commercial ELISA [72] 1 + 0 + 0 + 1 + 0 = 2
Neopterin Commercial ELISA [85] 1 + 0 + 0 + 1 + 0 = 2
NO Nitric oxide Spectrophotometry [95] 1 + 0 + 0 + 1 + 0 = 2
OPG Osteoprotegerin/TNF 11B Luminex assay
Commercial ELISA
[57] 1 + 1 + 1 + 1 + 0 = 4
[96]
OPN Osteopontin, phosphoglycoprotein Commercial ELISA [97] 1 + 0 + 0 + 1 + 0 = 2
RA33 Anti-heterogeneous nuclear ribonucleoprotein
A2 antibodies
Commercial ELISA [98] 1 + 0 + 0 + 1 + 0 = 2
RANKL TNF ligand superfamily member 11/receptor
activator of nuclear factor kappa B ligand
Commercial ELISA [96] 1 + 0 + 0 + 1 + 0 = 2
Resistin Protein adipokine Commercial ELISA [99] 1 + 0 + 0 + 1 + 0 = 2
S100A12 S100 calcium-binding protein A12 In-house ELISA
Commercial ELISA
[45] [45] 1 + 1 + 1 + 1 + 0 = 4
[100] [100]
[101] [102]
S100A8/A9 MRP8/14 (myeloid regulatory protein 8/14)
complex, complex of S100A8 (Calgranulin A)
and S100A9 (Calgranulin B)
In-house ELISA
Commercial ELISA




SAA Serum amyloid A Commercial ELISA [45] [45] 1 + 1 + 0 + 1 + 0 = 3
[76]
SAP Serum amyloid P Commercial ELISA [45] 1 + 0 + 0 + 1 + 0 = 2
sCD163 Soluble cluster of differentiation 163/haemoglobin
scavenging receptor
Commercial ELISA [85] 1 + 1 + 0 + 1 + 0 = 3
[104]
sCD21 Soluble cluster of differentiation 21 Commercial ELISA [105] 1 + 0 + 0 + 1 + 0 = 2
sCD23 Soluble cluster of differentiation 23/soluble low
affinity immunoglobulin epsilon Fc receptor)
Commercial ELISA [105] 1 + 0 + 0 + 1 + 0 = 2
sCD25 Soluble cluster of differentiation 25/soluble
interleukin-2 receptor alpha
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Fig. 2 Identified biomarkers grouped by clinical question. a Diagnostic biomarkers are shown that differentiated systemic juvenile idiopathic
arthritis (SJIA) from healthy controls (HC) or other non-JIA disease (D1), SJIA vs other JIA subtypes (D2) or both (D1 and D2). b Prognostic
biomarkers for flare (P1), increased disease activity or discriminating active disease from inactive (P2), for macrophage activation syndrome (MAS)
or discriminating MAS from SJIA flare (P3), or a combination of these are shown. The specific clinical question is very important in interpreting the
results of biomarker studies. Little overlap between different diagnostic questions suggests a predominance of different pathways during
different stages of disease and therefore a specific hypothesis and clinical question is more useful in studies to understand mechanisms. Biomarkers that
are broad enough to cover more than one diagnostic or prognostic category may be more likely to have a specific role in the underlying immunological
pathology, and as broad markers will be more useful for wider clinical care. By performing this analysis we can create a shortlist of biomarkers on which to
focus. Indeed, only a few markers fall into this group, but perhaps they should receive most attention for future validation in preference to other markers.
ACAN aggrecan core protein cartilage-specific core protein, ACCP anti-cyclic citrullinated peptide, ACPA anti-citrullinated protein antibodies,
ACT alpha-1-antichymotrypsin, AECA anti-endothelial cell antibodies, ANA antinuclear antibodies, Anti-BiP anti-immunoglobulin binding
protein/glucose regulated protein 78 (GRP78), APO apolioprotein, APRIL A proliferation-inducing ligand, B2M Beta -2-microglobulin, BAFF B-cell
activating factor, COMP cartilage oligomeric matrix protein, CRP C-reactive protein, FSTL-1 follistatin-like protein 1, GSN Gelsolin, HO-1 heme oxygenase-1,
IFN interferon, IL-18BP IL-18 binding protein, LGAL galectin, MMP matrix metalloproteinase, ONP osteopontin, SAA serum amyloid A, SAP
serum amyloid P, sICAM-1 soluble intracellular adhesion molecule-1, sST2 soluble ST2/IL-1 receptor-like 1, TIMP tissue inhibitors of metalloproteinase,
TTr transthyretin
Table 3 Identified serum and plasma biomarkers (Continued)
sE-selectin Soluble E-selectin adhesion molecule Commercial ELISA [108] 1 + 1 + 0 + 1 + 0 = 3
[109]
[110]
sICAM-1 Soluble intracellular adhesion molecule-1 Commercial ELISA [108] 1 + 1 + 0 + 1 + 0 = 3
[109]
[110]
sRAGE Soluble receptor for advanced glycation end products Commercial assay [83] 1 + 0 + 0 + 1 + 0 = 2
sST2 Soluble ST2, also called interleukin 1
receptor-like 1 (IL-1RL1)
Commercial ELISA [111] [111] 1 + 0 + 0 + 1 + 0 = 2
sTM Soluble thrombomodulin/CD141 Commercial ELISA [112] 1 + 0 + 0 + 1 + 0 = 2
sTNFR55 Soluble tumour necrosis factor receptor 55 Commercial ELISA [113] 1 + 0 + 0 + 1 + 0 = 2
sTNFR75 Soluble tumour necrosis factor receptor 75 Commercial ELISA [113] 1 + 0 + 0 + 1 + 0 = 2
Survivin Commercial ELISA [76] 1 + 0 + 0 + 1 + 0 = 2
TIMP Tissue inhibitors of metalloproteinases Commercial ELISA [96] 1 + 0 + 0 + 1 + 0 = 2
TNF-alpha Tumour necrosis factor-alpha Commercial ELISA [88] 1 + 0 + 0 + 1 + 0 = 2
TTR Transthyretin Commercial ELISA [45] [45] 1 + 0 + 0 + 1 + 0 = 2
aBiomarker scoring system (BMS) biomarker score: each answer is scored as follows: yes = 1, no = 0. D diagnostic, P prognostic, Q1 readily measurable (e.g. in
serum), Q2 measured by more than one independent study group, Q3 discovered by more than one single method, Q4 measured by a reproducible assay, Q5
validated in a validation cohort, IFN interferon, TNF tumour necrosis factor
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is much more variable, and might be reported as being
based on reproducibility, availability of antibodies or
levels of protein expression [44]. However, too often
these data are omitted, leading to bias in the selection
procedure. Ling et al. detected 26 proteins in plasma
from patients with SJIA, which differentiated flare from
quiescence plasma, of which 18 proteins were signifi-
cant, and from these the top 15 were selected for un-
supervised analysis and shown to remain significant [45].
However, only a limited panel of 9/15 were further
tested, chosen according to the availability of antibodies
and ELISA. As there is no quantitative and unbiased ap-
proach for prioritising candidate markers, we created the
novel but unvalidated BMS (Table 2) for this study.
We evaluated each identified biomarker (Table 3) using
the BMS (Table 2). No biomarker had the maximum score
(5/5). The highest-scoring markers (score 4/5) were HO-1,
IL-6, IL-12, IL-18, osteoprotogerin (OPG), S100A12 and
S100A8/A9 (n = 7). There were 10 and 51 biomarkers with
scores of 3/5 and 2/5, respectively. A score of 3/5 or
greater, therefore, identified 17 (25 %) of the total bio-
markers. The highest-scoring markers grouped according
to diagnostic or prognostic subgroup are indicated in
Fig. 1.
Next, the 36 identified D1 biomarkers, the largest
group of identified biomarkers for any of the clinical
questions asked, were scored and ranked as an example
to show how the BMS could prioritise candidates for
further evaluation (shown in Fig. 2, scores in Table 3).
Seven biomarkers scored 4/5 (as listed above) and seven
others scored 3/5, while the remaining 22 markers
scored 2/5. This resulted in a panel of 14 markers
when the cutoff was applied at a score of 3/5 or above
(or n = 15 when S100A8 and S100A9 were analysed as
separate proteins). Further ranking of markers within
these broad groups was not performed. The online
Search Tool for the Retrieval of Interacting Genes/
Proteins (STRING) platform was used to identify if
any of these 15 proteins had known functions in com-
mon [46]. To differing extents STRING identified dir-
ect or indirect functional link or interactions between
all proteins except S100A12, FSTL-1 and COMP
(when tested at the “medium” confidence level). All
proteins were identified to be extracellular, consistent
with their measurement in peripheral blood, and had
an identified immune function role. A summary of
the functions of this protein set is shown in
Additional file 2: Table S2.
The biomarker panel approach
Multiplex cytokine analysis can (1) differentiate SJIA
from differential diagnoses and (2) identify distinct pro-
files in individual patients. Identification of cytokinepatterns in individual patients could lead to the identifi-
cation of subphenotypes within SJIA and also provide
insight into the underlying biological basis for the clin-
ical heterogeneity seen in SJIA [47, 48]. This clinical
variation and the variety in identified biomarkers sup-
ports a prevailing view that a biomarker panel is re-
quired [8]. A “multimarker approach” is already used to
predict risk of cardiovascular events and the multibio-
marker assessment of disease activity (MBDA) is vali-
dated for rheumatoid arthritis (RA) [49–55]. The MBDA
outperforms clinical assessment alone, imaging and
single biomarker measurement, and is also cost-effective,
measuring 12 biomarkers in just 0.2 ml of serum. A po-
tential panel of biomarkers has recently been identified
for paediatric systemic lupus erythematosus, which had
good predictive value for detecting the complication
lupus nephritis [56]. Jager et al. identified cytokine pro-
files in paired plasma and synovial fluid samples in 20
patients with SJIA using a bead array based multiplex
immunoassay which measured 30 soluble inflammatory
mediators in only 50 μl of sample and showed the blind
measurement of IL-18 predicted patients with active
SJIA with 93 % accuracy [57, 58]. While the identified
studies in our analysis often evaluated more than one
candidate marker, combinations of markers were not
tested and did not feature in study hypotheses/design
and/or sample numbers.
Prerequisites for clinical biomarkers
Sample-specific and method-specific factors should be
considered before performing either discovery or valid-
ation studies [59]. Sample requirements differ according
to the planned methodology and platform to be used
[60, 61]. Some cytokines, such as IL-1β, are extremely
sensitive to degradation by freeze-thawing, whereas IL-
18 is comparatively more stable [61]. A clinical bio-
marker should also fulfil an unmet need and improve
existing tests, while also being cost-effective, criteria
which will also help define candidates for validation
[10, 59, 62]. We did not investigate the cost-effectiveness
of markers. However, the validation and clinical use of
many of the biomarkers, as described, is limited by the
cost and/or local availability of diagnostic tests.
Validation of biomarkers
Most candidate markers (86 %) were identified in a single
study and/or by a single group, respectively. While this in-
dicates that multiple groups are working on SJIA bio-
markers, each with different strategies, it also reflects a lack
of current understanding of the pathology of SJIA. Methods
of biomarker verification, as intermediary steps towards
validation, become increasingly important as new and im-
proved biomarker discovery techniques result in large num-
bers of candidates [35, 63]. Identification of the same
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verification step, suggesting a false positive finding to be
less likely. Other verification factors might include confirm-
ation that a candidate biomarker can be robustly measur-
able in peripheral blood, or the use of specific verification
methods such as proteomic mass-spectrometry-based se-
lected reaction monitoring (SRM) analysis [18]. SRM mea-
sures multiple target proteins, identified from discovery
studies or existing literature simultaneously, without requir-
ing specific antibodies as with antibody-based validation
techniques, but it does not replace validation.
Biomarker validation, most frequently performed using
antibody-based assays, is a difficult, costly and time-
consuming process [35]. An example of validation is the
included study by Rothmund et al. which compared
different assays for measuring S100-proteins in JIA
[21, 64]. Biomarker validation, also termed “qualification”,
can be separated from clinical validation as a process refer-
ring more specifically to the process of linking biomarkers
to a clinical endpoint based on evidence and statistical ana-
lysis [65]. Validation is widely acknowledged to be a more
difficult process than identification, due to the requirement
of large numbers of samples of well-defined patients from
populations not used in the discovery step. An example use
of a validated diagnostic biomarker or panel could allow
earlier diagnosis of SJIA, allowing treatment to be started
during the “window of opportunity”, the time point early
enough in disease that intensive targeted treatment could
be used to achieve early disease remission [8, 29, 66]. We
therefore focused on identifying potentially clinically rele-
vant diagnostic or prognostic biomarkers for SJIA from
studies addressing specific clinical questions.
Conclusions
There remains a need for the simultaneous evaluation of
multiple biomarkers and an unbiased method of select-
ing candidate biomarkers for further evaluation. The
parallel use of different methodological platforms such
as microbead arrays (e.g. Luminex xMAP), aptamer-
based assay or label-free liquid mass spectrometry (LC-
MS/MS) could improve the spectrum of detected pro-
teins [67], while the BMS used here is an example of
how candidate markers could be prioritised. Markers
that exclude SJIA would also be useful in the clinical set-
ting. In particular, markers diagnostic for the main dif-
ferential diagnoses of SJIA, such as the causes of fever of
unknown origin, which might include infection or malig-
nancy, would help exclude SJIA as a diagnosis. While
this review was not designed to explore markers of dif-
ferential diagnoses of SJIA, including them in a potential
multi-marker panel would likely improve such a diag-
nostic assay.
Sixty-eight unique candidate markers evaluated for the
management of SJIA were identified by this literaturereview. Only one identified study was a validation study
and very few identified biomarkers were evaluated by
more than one study group. Therefore, there is a clear
and urgent need to confirm and consolidate findings
from discovery studies and validate findings. The use of
emerging technologies, with collaborative efforts, may
ultimately help achieve the goal of validating new diag-
nostic or prognostic biomarkers, or panels of bio-
markers, for improving the management of SJIA.
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